
Researchers develop temporary tattoos that can test for spiked drinks
Published Wednesday by the American Chemical Society (ACS), the study from Korean researchers developed a multicoloured temporary tattoo that reacts to the presence of GHB, a compound described as 'commonly associated with drug-facilitated sexual assault.'
'These drugs are colorless and tasteless, inducing a stupor in the victim that's similar to severe alcohol intoxication,' reads a release from the ACS.
'Consuming a drink spiked with drugs including Rohypnol (commonly known as roofies) or GHB when drinking in a social setting is an ever-present danger — even among friends and acquaintances.'
According to the study, the chemicals in the tattoo can detect concentrations of GHB in beer, liquor or coffee, changing colour from yellow to red in order to alert the wearer that their beverage may have been spiked.
'In practice, a wearer could dip a finger into a beverage, touch the drop to the sticker and see the result almost immediately,' the release reads.
In recent years, scientists have developed a variety of products to check beverages for drugs, from chemical test strips to more inconspicuous options like nail polish, coasters and stir sticks.
The newly developed tattoos not only allow the users to test their drinks discreetly, but also act far faster than some older tests, delivering results in less than a second, rather than minutes.
Researchers also say the results last for up to a month, which can help preserve evidence of suspected tampering.
The tattoos are inexpensive to manufacture and 'could be commercially available soon,' according to the release.
With files from CTV News Vancouver's Andrew Weichel
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CBC
19 hours ago
- CBC
Organizations fighting gender-based violence get millions in funding
Services that support survivors of domestic violence and sexual assault will receive $9.2 million from New Brunswick government for this fiscal year.


CTV News
a day ago
- CTV News
York police charge doctor with two counts of sexual assault
Police in York Region have arrested a doctor on sexual assault charges. York's Criminal Investigations Bureau have charged a doctor with sexual assault after a victim reported two incidences. Police say the person attended a medical clinic on Markham Road. During the visit, the person said the doctor touched them in a sexual manner. The victim left immediately and reported the incident to the police. While telling police of the experience, the person also recalled a previous appointment at the same clinic in November 2023, when the doctor's actions were also inappropriate. At that time, the person didn't report the event because they believed the conduct might have been part of a legitimate medical procedure. Police are asking the public to review the photo of Dr. Saber Abdel Malouka Abdel Malak, 62, of Whitchurch-Stouffville who has been a physician for more than 30 years. Police say a sexual assault includes any non-consensual contact of a sexual nature. They encourage anyone who feels they may have been a victim to report the incident to the police. To make an online report click here. Anyone with information is asked to call the York Regional Police Special Victims Unit at 1-866-876-5423, ext. 7071. Anonymous tips can be made by calling Crime Stoppers at 1-800-222-TIPS.


Globe and Mail
4 days ago
- Globe and Mail
Pfizer's PAXLOVID Study: Real-World Insights on COVID-19 Treatment
Pfizer Inc ((PFE)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Pfizer Inc. is conducting a study titled 'Post Marketing Surveillance to Observe Safety and Effectiveness of PAXLOVID in Patients With Positive Results of Viral Testing, and Who Are at High Risk for Progression to Severe COVID-19.' The study aims to assess the real-world safety and effectiveness of PAXLOVID in patients at high risk of severe COVID-19, particularly in Korea. This is significant as it provides insights into the drug's performance outside controlled clinical settings. The intervention being tested is PAXLOVID, an antiviral treatment intended to reduce the severity of COVID-19 in high-risk patients. The study focuses on patients who have tested positive for the virus and are at risk of severe outcomes, including hospitalization or death. This observational study follows a case-only model and does not involve any specific allocation or masking. The primary purpose is to gather real-world data on PAXLOVID's effectiveness and safety over a 28-day follow-up period after treatment. The study began on November 29, 2023, with its primary completion and estimated study completion dates yet to be announced. The last update was submitted on July 22, 2025, highlighting ongoing data collection and analysis. Market implications of this study are significant for Pfizer's stock performance as positive real-world data could bolster investor confidence and market position against competitors. The study's outcomes may influence healthcare providers' decisions and potentially increase PAXLOVID's market share. The study is currently recruiting, with further details available on the ClinicalTrials portal.